AFP and hepatocellular carcinoma: Indeed, Galunisertib has been tested as second-line monotherapy in 149 HCC patients in a phase II study (Table 3), predefining baseline AFP values as a biomarker (greater than 400 ng/mL) (NCT01246986) [162].